Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Tax Provisions (2016 - 2025)

Ligand Pharmaceuticals' Tax Provisions history spans 16 years, with the latest figure at $12.0 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 247.88% year-over-year to $12.0 million; the TTM value through Dec 2025 reached $34.5 million, up 426.82%, while the annual FY2025 figure was $34.5 million, 426.82% up from the prior year.
  • Tax Provisions for Q4 2025 was $12.0 million at Ligand Pharmaceuticals, down from $23.9 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $38.7 million in Q4 2022 and bottomed at -$13.5 million in Q2 2024.
  • The 5-year median for Tax Provisions is $2.1 million (2021), against an average of $4.4 million.
  • The largest annual shift saw Tax Provisions surged 2934.72% in 2021 before it tumbled 1629.97% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $4.1 million in 2021, then soared by 847.43% to $38.7 million in 2022, then crashed by 102.82% to -$1.1 million in 2023, then crashed by 643.54% to -$8.1 million in 2024, then surged by 247.88% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Tax Provisions are $12.0 million (Q4 2025), $23.9 million (Q3 2025), and $6.4 million (Q2 2025).